InPenTM Copay Program

InPen is a Bluetooth enabled, reusable, smart insulin delivery pen, with half-unit dosing. In combination with a continuous glucose monitor (CGM), the app will help calculate the right insulin dose for meals and corrections, provide reminders to take your insulin, and track your history of insulin doses.

Remembers. Reminds. Recommends. 

So you don’t have to.

Proper pairing, connectivity, and settings required or incorrect dosing and serious injury can occur. See user guide for full details.

Pay as little as $125 for InPen — One copay for a smart insulin pen that lasts 12 months

Your copay may be less. Eligibility for customers with commercial insurance only.

If InPen is covered on your commercial health insurance plan, your copay may be $30 - $90. If you have not met your deductible or InPen is not covered, pay as little as $125 for one InPen.

Individual copays will vary. Terms and conditions apply.

Order InPen

InPen Copay Program terms and conditions

Open to insured patients and patients with commercial prescription insurance and those who are not enrolled in any government-funded program that pays for prescription devices or treatments.
Excluded participants include patients enrolled in any federal, state, or government-funded healthcare program such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® that provides coverage for InPen, or where prohibited by law.
Cash Discount Cards and other non-insurance plans are not valid as primary under this offer.
Offer subject to change or discontinue without notice. This is not health insurance.
Offer applies to a maximum of 1 prescribed InPen per Patient per benefit year.
Offer good only in the USA at participating pharmacies and cannot be redeemed at government-subsidized clinics.

Important Safety Information: InPen system

The InPen system consists of a reusable insulin pen and mobile app and is for people living with diabetes. It can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals. Those under the age of 7 should only use the device with an adult’s supervision. A healthcare provider must prescribe InPen, provide dosage settings, and discuss all potential benefits and risks. Using the device with incorrect therapy settings may lead to severe highs and lows. The system should not be used by those unable to test blood glucose levels or the visually impaired. For additional safety information and user guides, see https://bit.ly/MiniMedRisks.

 

Important safety information: MiniMed Go system

The MiniMed Go system includes the MiniMed Go app, InPen smart insulin pen injector and either the Instinct continuous glucose monitoring (CGM) sensor or Simplera CGM sensor. The system is intended to aid in diabetes management through multiple daily injections of compatible rapid-acting insulins (Humalog, Novolog, or Fiasp). The app and system components each require a prescription. When used with Instinct CGM, the app is indicated for patients ages 7 years and older, or patients ages 2 to 6 years under the supervision of an adult caregiver. When used with Simplera CGM, the app is indicated for patients ages 18 and over. If using InPen alone, the app is intended for all ages, with patients under age 7 requiring supervision. Use of these systems requires, among other things, adequate hearing and vision, a compatible mobile device and operating system, an open app, adequate pairing and connectivity, proper setting, use of an approved rapid-acting insulin, mobile device battery power, proper settings, accurate manual logging of insulin doses administered by means other than InPen, and occasional blood glucose meter (BGM) readings. Establishment of settings and treatment decisions should be made in consultation with a healthcare professional and on the basis of a combination of glucose readings, trend arrows, glucose target, active alerts, and recent events (such as insulin doses, exercise, meals, and medications). Failure to observe these and other details as found in the user guides can result in incorrect dosing, missed alerts and notifications, and ultimately hypoglycemia or hyperglycemia, with serious injury or death possible. For additional safety information and user guides, see https://bit.ly/MiniMedRisks.